| scholarly article | Q13442814 |
| P2093 | author name string | Li Zhao | |
| Dong Wook Kim | |||
| Sheue-Yann Cheng | |||
| Mark C Willingham | |||
| Xuguang Zhu | |||
| P2860 | cites work | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 |
| Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor | Q27853093 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| Histone acetylation in chromatin structure and transcription | Q28131749 | ||
| Lost in transcription: p21 repression, mechanisms, and consequences | Q28251319 | ||
| Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug | Q28282479 | ||
| The landscape of somatic copy-number alteration across human cancers | Q29547648 | ||
| Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 | ||
| FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma | Q33377159 | ||
| Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma | Q33381498 | ||
| Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. | Q33390876 | ||
| Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study | Q33391851 | ||
| Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways | Q33736109 | ||
| Src-dependent ezrin phosphorylation in adhesion-mediated signaling | Q33914506 | ||
| Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor | Q34478795 | ||
| Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation | Q34528284 | ||
| Histone deacetylases and cancer: causes and therapies | Q34570082 | ||
| Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression | Q35070405 | ||
| TSH-activated signaling pathways in thyroid tumorigenesis | Q35736825 | ||
| PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer | Q36278234 | ||
| Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor | Q36439404 | ||
| Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells | Q36715993 | ||
| Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor | Q36748109 | ||
| Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine–Refractory Thyroid Carcinoma | Q36813563 | ||
| Histone deacetylase inhibitors: molecular mechanisms of action | Q36908440 | ||
| Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone | Q37288003 | ||
| Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers | Q37667088 | ||
| Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer | Q37767709 | ||
| Radioiodine for remnant ablation and therapy of metastatic disease | Q37913996 | ||
| HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications | Q37962333 | ||
| Mechanisms of Resistance to Histone Deacetylase Inhibitors | Q38054220 | ||
| p21WAF1 and tumourigenesis: 20 years after | Q38060451 | ||
| Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment | Q39525953 | ||
| Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance | Q39744464 | ||
| Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. | Q39791600 | ||
| Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma | Q39981886 | ||
| Akt- and MAPK-mediated activation and secretion of MMP-9 into stroma in breast cancer cells upon heregulin treatment. | Q40029865 | ||
| The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells | Q40098928 | ||
| Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo | Q40227787 | ||
| Novel histone deacetylase inhibitors in the treatment of thyroid cancer | Q40422202 | ||
| Crosstalk between the Rb pathway and AKT signaling forms a quiescence-senescence switch | Q46909608 | ||
| Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis | Q52548664 | ||
| Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer | Q53330585 | ||
| P433 | issue | 7 | |
| P921 | main subject | carcinogenesis | Q1637543 |
| P304 | page(s) | 521-533 | |
| P577 | publication date | 2016-06-07 | |
| P1433 | published in | Endocrine-Related Cancer | Q3054004 |
| P1476 | title | SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model | |
| P478 | volume | 23 |
Search more.